MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-03-2026
Agilent Technologies Book Value 2011-2026 | A
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Agilent Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.39 B | 4.87 B | 4.75 B | 4.57 B | 4.84 B | 4.25 B | 4.17 B | 5.3 B | 5.29 B | 5.18 B | 4.32 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.39 B | 4.17 B | 4.81 B |
Quarterly Book Value Agilent Technologies
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.91 B | 6.74 B | 6.37 B | 6.03 B | 5.9 B | - | - | 5.78 B | 5.15 B | 5.3 B | - | 5.12 B | 4.8 B | 5.39 B | 4.95 B | 5.39 B | 4.85 B | 4.87 B | 4.87 B | 4.77 B | 5.04 B | 4.75 B | 4.75 B | 4.75 B | 4.53 B | 4.6 B | 4.6 B | 4.6 B | 4.3 B | 4.84 B | 4.84 B | 4.84 B | 4.05 B | 4.25 B | 4.25 B | 4.25 B | 4.24 B | 4.17 B | 4.17 B | 4.17 B | 5.45 B | 5.3 B | 5.3 B | 5.3 B | 5.35 B | 5.29 B | 5.29 B | 5.29 B | 4.5 B | 5.18 B | 5.18 B | 5.18 B | 3.34 B | 4.32 B | 4.32 B | 4.32 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.91 B | 3.34 B | 4.94 B |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
44.4 M | $ 1.16 | -1.69 % | $ 6.32 M | USA |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
303 M | $ 16.69 | -6.86 % | $ 889 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 16.25 | 0.06 % | $ 175 M |  China |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | USA |
 |
Co-Diagnostics
CODX
|
20.6 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
456 M | $ 23.43 | -6.99 % | $ 651 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
3.21 B | $ 175.55 | 0.27 % | $ 8.7 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
Danaher Corporation
DHR
|
83.5 B | $ 192.99 | -1.63 % | $ 138 B | USA |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
22.4 M | $ 2.3 | 16.02 % | $ 10.2 M | USA |
 |
Illumina
ILMN
|
6.3 B | $ 123.67 | -3.38 % | $ 19.7 B | USA |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 15.02 | -5.12 % | $ 454 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
11 B | $ 28.13 | 0.29 % | $ 20 B |  Niderland |
 |
Guardant Health
GH
|
-99.3 M | $ 87.17 | -6.11 % | $ 10.9 B | USA |
 |
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
14 M | $ 2.74 | 0.37 % | $ 88.9 K | USA |
 |
Biomerica
BMRA
|
4.1 M | $ 2.2 | 2.33 % | $ 5.05 M | USA |
 |
ICON Public Limited Company
ICLR
|
9.52 B | $ 106.7 | 0.15 % | $ 8.8 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M |  Israel |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 273.26 | -0.53 % | $ 22.7 B | USA |
 |
Celcuity
CELC
|
101 M | $ 124.64 | 6.58 % | $ 5.83 B | USA |
 |
Medpace Holdings
MEDP
|
459 M | $ 501.5 | -3.68 % | $ 14.5 B | USA |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 81.43 | 1.75 % | $ 5.5 B | USA |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
Myriad Genetics
MYGN
|
368 M | $ 4.44 | -6.92 % | $ 411 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 197.82 | -0.5 % | $ 22 B | USA |
 |
NeoGenomics
NEO
|
837 M | $ 7.94 | -3.38 % | $ 1.02 B | USA |
 |
Neogen Corporation
NEOG
|
2.07 B | $ 10.04 | -2.95 % | $ 2.18 B | USA |
 |
ENDRA Life Sciences
NDRA
|
2.26 M | $ 5.31 | 2.71 % | $ 4.18 M | USA |
 |
National Research Corporation
NRC
|
14 M | $ 17.05 | -1.22 % | $ 382 M | USA |
 |
Natera
NTRA
|
706 M | $ 203.0 | -3.71 % | $ 20 B | USA |
 |
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
10.5 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
7.38 M | - | -16.95 % | $ 1.54 M | USA |